Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental paracetamol formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Experimental paracetamol formulation | EXPERIMENTAL | test formulation |
| Marketed paracetamol | ACTIVE_COMPARATOR | Marketed paracetamol |
| Higher dose marketed paracetamol | ACTIVE_COMPARATOR | higher dose marketed paracetamol |
| Name | Type | Description |
|---|---|---|
| Experimental paracetamol formulation | DRUG | experimental |
| Marketed paracetamol | DRUG | Marketed paracetamol |
| Higher dose marketed paracetamol | DRUG | Higher dose marketed paracetamol |
Inclusion Criteria: * Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination. Exclusion Criteria: * Subject does not agree to refrain from alcohol consumption for the 10-day period prior to visi...
Experimental paracetamol is an investigational small molecule being studied for the treatment of tension-type headache and in healthy subjects. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Experimental paracetamol is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK.
Experimental paracetamol is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and pharmacokinetics.
Experimental paracetamol has been studied in two completed Phase 1 clinical trials: NCT01476176, a pharmacokinetic study in patients with tension-type headache, and NCT01476189, a study comparing the pharmacokinetic profile of two paracetamol formulations in healthy subjects.
Experimental paracetamol is an investigational formulation of paracetamol, also known as acetaminophen. It is being studied to evaluate its pharmacokinetic profile compared to other paracetamol formulations.